Posted on 539
ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has entered into an exclusive global patent license agreement with Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI) providing rights to CISH KO in the field of NK cells for the treatment of cancer.
“Deletion of CISH in NK cells leads to an improved metabolic profile, greatly enhances their proliferation, cytotoxicity, and persistence.
In-vivo models of cancer have shown that CISH KO NK cells are much more efficient in eliminating cancer cells, making such cells a very attractive prospect for future clinical development,” said Prof Michael O’Dwyer, CSO of ONK Therapeutics.
Cytokine Inducible SH2 containing protein (CIS; encoded by the gene CISH) is a potent checkpoint in NK cell-mediated tumor immunity CISH knockout (KO) NK cells have been shown to be more efficient
ONK Therapeutics Secures Exclusive Global License to Patent for CISH Knockout in NK Cells for the Treatment of Cancer, from Australia's WEHI pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.